Index

2,3-DPG 12–13, 16–18, 110–12, 219, 247–9, 251
10/30 rule of Adams and Lundy 4–5, 246
A-ANH (augmented ANH) 207–8
see also acute normovolemic hemodilution
abdominal packing techniques 185, 313
ABL see allowable blood loss
absolute iron deficiency 39–43, 48
absolute/relative fluid losses 68–9
ACE see angiotensin-converting enzyme
acellular HBOCs 111–12, 206
activated coagulation time (ACT) 167–8
activated partial thromboplastin time (aPTT) 145, 147, 152–3, 167–8, 169–70
activated prothrombin complex concentrates (aPCCs) 231–2
active bleeding risk factors 250–2, 256, 257, 299
acute anemia 9, 13–20, 257
acute hypervolemic hemodilution (AHH) 201, 204–5, 313
see also autologous blood;
hemodilution definition 201, 204
equation 204
acute normovolemic hemodilution (ANH) 201, 202, 204, 205–8, 280, 293–4, 313, 317
see also autologous blood;
hemodilution
A-ANH (augmented ANH) 207–8
concepts 201, 202, 204, 205–8
costs 207
critique 205–7, 208
definition 201, 202, 204, 205
eligibility criteria 205, 209
equation 205
historical background 202
modifications 207–8
postoperative anemia 208
risks 205–6
theoretical basis 205–6
troubleshooting 206
Adams, R.C. 4–5, 7, 246
ADAMTS-13-related thrombotic thrombocytopenic purpura 257–8
adaptation mechanisms to anemia 9, 13–20
adenosine triphosphate (ATP) 13, 17–18, 53, 194, 247–9
adjuvant therapies 21, 26–32, 48
administration of blood management programs 6–7, 262–82, 309–22
see also blood management programs
adrenergic system 13–14
adrenochrome, hemostatic drugs 89
adultery 292
advance directives (living wills) 289, 295
advertising restrictions 282–3, 314, 316–19
aerobic metabolism 10, 13, 16–17
age factors, surgery preparations 141
AHM see acute hypervolemic hemodilution
air embolism risks, cell salvage 221
Al-Razi 174
Al-Zahrawi 174
ALA see aminolevulinic acid
albumin 4, 71, 73–5, 78, 91–2, 100–8, 116, 181, 229–41, 248–9, 292–4, 300
see also colloids; plasma . . ;
recombinant human serum . .
costs 73
definition 71, 73–4, 234
side effects 73–4, 75, 101
tissue adhesives 91–2
Alexander the Great 124
alginate colloid solutions 73, 78
algorithms 4, 139–40, 145–6, 155, 168, 256, 270–1, 275, 305–7, 311–13, 317–18
Allen, J.G. 5
allergic reactions 24, 73, 75, 144, 165, 247
see also principles; transfusions
10/30 rule of Adams and Lundy 4–5, 246
benefits’ assessments 247, 250–2, 287
BRAND decision-making
mnemonic 247, 250–8
cell salvage comparisons 218–19, 223, 287

© 2013 John Wiley & Sons, Ltd. Published 2013 by John Wiley & Sons, Ltd.

327
positioning factors 187, 192–3
WHO blood management
definition 3
blood management
see also individual topics
anxieties 273
barbaric practices 245–6
benefits 1–8, 262–82, 320
biotechnology 100–8
charters and bills 285–6, 287–91
competence centres 262
definitions 1, 3, 262, 287
future prospects 4, 5, 120
good clinical practice aspects 1, 5–8
historical background 1–8, 67–8, 81–2, 100–1, 109–10, 160–1, 173–5, 201–2, 212–13, 229–30, 245–6, 324–6
iatrogenic blood loss 160–72, 275, 281, 313, 317
Jehovah's Witnesses 1–3, 5, 6, 263, 265, 285, 291–5, 317
law 2, 6–7, 270–1, 272, 273, 282–3, 285–96, 318, 323–4
literature 5, 305–8
medical organizations 5, 305–8
multidisciplinary approaches 1, 6–8
religions 1–3, 4, 5, 6, 141, 174, 263, 265, 285, 291–5, 317
blood management programs 1, 2–3, 5, 6–7, 262–84, 309–22

see also education
administration 6–7, 262–82, 309–22
benchmarking 268, 281–2
benefits 1–8, 262–82, 320
budgets 265–7, 278, 316–17, 320
business plans 264–7, 269, 281, 320
champions 267–8, 269–70, 272–82
change processes 271–8
communication skills 6–7, 262, 264–5, 269–70, 314–15
computer systems 275, 279–81, 314–16
concepts 262–82, 309–22

core teams 269–70
costs 264, 265–7, 278, 320
databases 279–81, 310–12, 314–16
definitions 262
error logs 282
forms' design 280–1, 321–2
hospital administration support roles 268–9, 272
implementation 267–8, 271, 278–81
informal/formal business proposals 264–5
initial analysis 263–4, 267, 270–1, 310–12
initiators 262–4, 267–8, 269–70
ISO requirements 271
marketing 262, 278, 282–3, 316–19
meetings 269–70, 321
motivation needs 263–4
multimodal approaches 1–8, 208, 270–1
oral presentations 264–5
organization 1–8, 262–82, 309–22
policies and procedures 6–7, 262, 270–82, 305–7, 315–17
presentations 264–5
priority-setting processes 279, 281
problems and requirements analysis 262, 264, 265, 278, 279, 281, 320
progress-monitoring methods 265–6, 272, 273, 281–2
resistance problems 264, 272–3
responsibilities 267, 269–70
returns on investments 265–7, 320
routine tasks 280–1
running the program 278–81
safety systems 281–2
stakeholders 263, 264–5, 269–70, 314–15
steering committees 269–71
steps 262–82
structural issues 267, 269–70
structured educational interventions 272–3
timing factors 264, 265–7, 320
transfer forms 281, 316, 321–2
website resources 263, 265, 308, 318

Blood, Medicine and the Law of God
(Jehovah's Witnesses) 2

see also volume therapy
blood quality factors, cell salvage 217–19, 221–2
blood viscosity levels 11–12, 14–18, 69–79, 111–13, 117, 207–9, 302
see also hemodilution
blood volume (BV), surgery preparations 139, 140, 148–56, 204–8
blood-derived pharmaceuticals 229–44
see also medications; plasma fractions
blood management uses 237–41
historical background 229–30
risk 239–40
usage-reduction approaches 240–1
blood-letting practices 5
bloodless medicine and surgery 1–3, 5, 183, 187, 308
‘bloodless’ monitoring alternatives, phlebotomy 162–3
bloodless programs, historical background 2–3, 5
Blundell, James 4, 212, 246
body system reviews, surgery preparations 143–4
Boerema’s demonstration 126
bolus infusions, fluid management 76
Bonaparte, Napoleon 154–5
bone marrow 21–32, 36–7, 53–64, 163, 218, 236, 257, 291, 293–4
see also erythropoiesis
bone wax, tissue adhesives/sealants (glues) 92
Bovie, W.T. 174, 178
see also electrosurgery
bowel gases, electrosurgery dangers 178
Boyer, Herbert 100
Boyle's decomposition phenomenon 125
Boyle's Law, definition 126, 129
the brain 13–18, 25
BRAND decision-making mnemonic, transfusions 247, 250–8
British Medical Journal 125
brochures/pictures/charts/tables, education 277, 312, 321
budgets for blood management programs 265–7, 278, 316–17, 320
Bull, W.T. 4, 68
Bunsen solubility coefficient 10
burn patients, surgery preparations 148, 164, 195
burst-forming units erythroid (BFU-E), erythropoiesis 22–32, 52
business plans, blood management programs 264–7, 269, 281, 320
BV see blood volume
c-Mpl 53–6
Cl1–esterase inhibitor 234, 240, 300
C2/C6 ratio 72–3
cABCDE algorithm 4
cadaver blood, historical background 4
Caesarean section 198, 204, 221, 224, 225
calcium, serum calcium levels 10
calcium alginate, hemostasis 94
calcium ions 70, 248–9
Canada 2–3, 263, 308
Canady, Dr Jerome 175
cancer surgery 2, 270
cancer-progression possibilities
growth factors 59–61
iron 38–9
rHuEPO 25, 29
cancer-related anemia, rHuEPO 25, 29–30

cell salvage 219, 221, 223–4
surgery preparations 143–4, 154
capillaries 11–12, 15–18, 118, 127, 251–8
see also functional capillary density; microvasculature . . . adaptation mechanisms to anemia 15–18
capillary–tissue oxygen gradient 11–12, 127
carbazochrome, hemostatic drugs 82, 89
carbon, PFCs 109–10, 116–21
carbon dioxide 10–11, 12–13, 15–18, 126–7, 129, 162, 224–5
cardiac output (CO), oxygen delivery equation 9–10, 13–14, 17, 76–7, 112–13, 116, 129, 192–4, 302
cardiopulmonary bypass 166–8, 205–6, 208, 217, 225
see also extracorporeal circulation
cardiovascular system review see also heart
surgery preparations 143, 154
care plans 6–7, 139–40, 149–50, 155, 313, 324
catalase (CAT) 111, 114
cautery 173–87
see also electrocautery; physical methods of hemostasis
cavitron ultrasonic surgical aspirator (CUSA) 181–2
see also vibration uses in surgery
CD4 T-helper lymphocytes 237–8, 253
CD8+ cytotoxic T lymphocytes 253
cell salvage 3–4, 6, 212–28, 272–3, 286–7, 293, 313, 317
see also autologous blood
allogeneic blood comparisons 218–19, 223, 287
amniotic fluid 222, 224, 225
antibiotics 218, 223
bacterial contamination concerns 221, 222–3, 225
blood counts 217–18
blood management 218–26, 286–7
blood quality factors 217–19, 221–2
centrifugation cleaning methods 215–17, 219–21, 222–5
centerline changes, adaptation mechanisms to anemia 15–18

cell salvage 3–4, 6, 212–28, 272–3, 286–7, 293, 313, 317
see also autologous blood
allogeneic blood comparisons 218–19, 223, 287
amniotic fluid 222, 224, 225
antibiotics 218, 223
bacterial contamination concerns 221, 222–3, 225
blood counts 217–18
blood management 218–26, 286–7
blood quality factors 217–19, 221–2
centrifugation cleaning methods 215–17, 219–21, 222–5
centers, iatrogenic blood loss 164–5, 169–70
central nervous system (CNS) 13, 25, 304
centrifugation cleaning methods 215–17, 247–9
CERA see continuous EPO receptor activator
cerebral effects, oxygen 128
CFU-E see colony-forming units erythroid
CFU-S see colony-forming units spleen
chambers, hyperbaric oxygen therapy 132–3
champions, blood management programs 267–8, 269–70, 272–82
change processes, blood management programs 271–8
channel arrest changes, adaptation mechanisms to anemia 17–18
Charles' Law, definition 126
charters 285–6, 287–91
see also law; principles; rights
chemistry, hemostasis 81–95
chemotaxis 53, 59–61
chemotherapy patients 28, 29–30, 58, 61–3, 163, 165, 270
CHHDA 112
chicken eggs, immunoglobulins 105
childbirth see also pregnancy
deaths 4
rHuEPO therapy 28, 32
Chinese hamster ovary cells (CHOs), recombinant blood products 23, 101, 104
chitosan, tissue adhesives/sealants (glues) 93
Chlamydia pneumoniae 297
chloramphenicol 238
chloride, sodium chloride crystalloid solution 70–1
choice rights 287–90
Index 333

crystalloids 19, 67–79, 204–8, 221, 293–4
see also electrolytes; fluid management; hemodilution balanced/unbalanced solutions 69–71, 77–8 concepts 67–79, 204–8, 221 definition 67, 69 side effects 74–5, 77–8 types of solutions 69–71
CSFs see colony stimulating factors
cT see computerized tomography
Cunningham, Dr Orval 125–6
CUSA see cavitron ultrasonic surgical aspirator
cushing, H. 174
customers 262, 278, 287, 316–19
cyanoacrylates, tissue adhesives/sealants (glues) 92
cyanosis 109
cyclophosphamide 24–5, 238
cyclosporine 24–5
cylinders, oxygen therapy 130–2
cystectomy 195
cytomegalovirus (CMV) 236, 297
cytoplasm 36–7
cytotoxic T lymphocytes 253 see also CD8 .
da Vinci, Leonardo 14
daily clinical rounds, education 274
Dalton (Da), definition 303
Dalton’s Law 10, 126
dam, Henrik 82
danaparoid 221
danazol, anemia treatments 31, 32, 152–4
darbepeotin, erythropoiesis-stimulating agents 30, 31
databases, blood management programs 279–81, 310–12, 314–16
Davenport, Henry 125
DDAVP see desmopressin
de Chauliac, Guy 174
dead space volume, phlebotomy 161–3, 168–70
see also ethics; law; principles algorithms 4, 139–40, 145–6, 155, 168, 256, 270–1, 275, 305–7, 311–13, 317–18
biased decision-making 247, 251
BRAND decision-making mnemonic 247, 250–8
conscience 290–1
definition 256, 285
grid analysis 256, 258
structured/unstructured decisions 256
transfusions 139–40, 145–6, 155, 168, 245, 246–58
Declaration on the Promotion of Patients’ Rights in Europe (1994) 287–8
dedicated teaching programs, education 276, 323–6
deep vein thrombosis 252, 280
deFelippe’s work 68
deformability abilities, red blood cells 11, 247–9, 251–2
deliberate hypotension see controlled hypotension
Denise, Jean Baptiste 4
deoxy myoglobin 13, 251
desflurane 194–5, 197
desiccation, definition 173
desmopressin 82, 84, 85–6, 88, 89, 94, 103, 151–4, 156, 231–2, 238, 239, 241, 299, 311, 313, 317
see also hemostasis
FVIII release 82, 231, 241
side effects 86
detailed information, appendices 297–304
dextran 3, 68, 70–1, 73, 74–5, 78, 111–12
see also colloids
definition 73
historical background 3, 68
side effects 74–5
diabetics 134, 143, 148, 169–70, 195
diagnostic procedures 3, 9, 130, 141–2, 144, 160, 164–5, 168–70
see also arterial lines; central lines; tracheostomy
education 164–5
iatrogenic blood loss 160, 164–5, 168–70
Diamond–Blackfan anemia, treatments 31, 63
diathermy 173, 174–87
see also electrosurgery
definition 173, 177, 178
scalpel contrasts 176
diazepam 134
DIC see disseminated intravascular coagulation
digestion, oxygen consumption 13
dignity and human care rights 287–90
dihydroequilin 81
direct cell salvage 212–15, 217–18, 219, 221–5
see also cell salvage
dispersion concepts, colloids 71–2
disseminated intravascular coagulation (DIC) 231, 233, 239
DMT1 protein 38–41
DNA 36–7, 44–5, 100–8, 176, 248–9
see also recombinant blood products
documentation
self-education material 263, 275–6
surgery preparations 141
drains 186, 192–3, 208, 213–26
see also physical methods of hemostasis
Drebbel, Cornelius 124
drugs see medications
Duncan, John 213
dysfibrinogenemia 231
dyspnea 128, 141–2
E-aminoacproic acid (EACA) 82, 84–5, 89, 95
see also antifibrinolytics; hemostasis
EACA see E-aminoacproic acid
eating benefits, peptic ulcers 164
Eber Papyrus 174
EBL see expected blood loss
ECC see extracorporeal circulation
edema 73–4, 76–7, 207, 251
education
brochures/pictures/charts/tables 277, 312, 321
combinations of methods 277–8
conferences 274
content issues 272, 273
continuous aspects 277–8
daily clinical rounds 274
dedicated teaching programs 276, 323–6
definitions 262

diagnostic procedures 164–5

feedback uses 271–2

formal one-to-one education 274, 277–8, 321

hospital fairy tales 324–6

informal one-to-one education 274

initiators of blood management programs 263–4

lectures and grand rounds 274

literature articles 276, 305–8

methods 263, 271–2, 273–8, 312, 323–6

needs’ assessments 271–3

participants 271–2

patient education benefits 154, 163, 272

peer reviews and audits 274, 275, 277–8, 312

phlebotomy 162–3

physical exercise 163

progress-monitoring methods 272, 273

prospective reviews 275

reading assignments and journal clubs 275–6

role plays 277

samples of equipment/drugs 277

self-education material 263, 275–6

stories 324–6

structured educational interventions 272–3

students 272–8, 323–6

tools 276, 323–6

videotapes 276–7

Edwin Smith Papyrus 174

EEGs see electroencephalograms

Ehinger, C.E. 125

Ehlers–Danone syndrome 143

EKGs see electrocardiograms

electrical currents for surgery 173, 177–8, 181

see also electrocautery; electrosurgery; physical methods of hemostasis; radiofrequency ablation

electrocardiograms (EKGs) 134–5, 195

electrocauter 173, 177–9

see also cautery; physical methods of hemostasis

electrocoagulation 173

electroencephalograms (EEGs) 195, 250

electrolytes 13–18, 67–79

see also crystalloids

electrons, iron 37–41

electrosurgery 173, 174–87

see also diathermy; physical methods of hemostasis

critique 178

definition 173, 177–8

high-frequency water jets 181

historical background 174–5

types 178

electrothermal bipolar vessel sealer 179

see also electrical currents for surgery

el thrombopag 55, 61–2

see also non-peptide TPO agonists

ele thrombopag 55, 61–2

see also non-peptide TPO agonists

embolization 183, 221, 313

epidermal regeneration 221

emergency transfers, administration of blood management programs 6–7, 281, 316, 321–2

equivalents, definition 303

error logs, blood management programs 282

erythrocytes see red blood cells


see also bone marrow; hematinics; kidneys; red blood cells

cytokines 21, 26–32, 36, 163

definition 21, 36, 51

EPO in normal conditions 21–3

HBOCs 115

oxigen therapy 136

PADs 202–4

physical exercise 163

physiology 36–7, 128–9

steps 21–3, 36–7

erththropoiesis-stimulating agents 30–1

see also recombinant human erythropoietin

erththropoietin (EPO) 18, 21–32, 47–8, 124–5, 128–9, 133, 256, 293–4, 313, 317

see also kidneys; recombinant human . . .

altitude effects 128–9

anemia treatments 18, 21–32

circadian cycles 22

definition 21–2

hematinics 26–7, 47

hyporesponsiveness 25–30

liver 21–2, 25

normal erythropoiesis 21–3

production processes 22–3, 25, 36–7, 128–9

protective effects 25

receptors 22–32, 52–3

regeneration effects 25

synthesized EPO 25

Escherichia coli (E. coli) 54–6, 100, 104, 105, 110–11, 114

Esmarch bandage techniques 183–4

Esmarch’s limb exsanguination technique 174

Esperanza Intercommunity Hospital in Yorba Linda, California 2

estradiol 81

estrogens 81, 88, 89, 152, 156, 311

ethersylet, hemostatic drugs 89


see also autonomy . . .

beneficence . . .; justice . . .; law; principles; respect . . .; rights

compassionate use 285, 294–5, 317

concepts 285–96, 318, 323–6

conscience 290–1
Index 335

definition 285
Jehovah’s Witnesses 1–3, 5, 6, 285, 291–5
ethnicity/race information 141, 288
ethinylestradiol 88
Europe 2–3, 287–90, 294
European Charter of Patients’ Rights
(Nice Charter of Fundamental Rights) 287–8, 294
evidence-based medicine tenets 251, 256–8, 305–7
expected blood loss (EBL), surgery preparations 140, 145–56, 204–6
expert systems 256
extracorporeal circulation (ECC) 160, 166–9
see also cardiopulmonary bypass;
hemodialysis patients; ventricular assist devices
definition 166
factor eight inhibitor bypassing activity (FEIBA) 231–2, 299
factor I see fibrinogen
factor II (FII) 103, 147, 149–2, 239, 299–300
factor III (FIII) 299–300
factor IV (FIV) 299–300
factor V (FV) 147, 147, 149–2, 239, 257–8, 299–300
factor Va (VFa) 233
factor VII (FVII) 4, 88, 103, 147, 231, 233, 239, 299–300
factor VIIa (VIIa) 4, 103–4, 106, 156, 237–9, 258
see also recombinant human FVIIa
factor VIII (FVIII) 82, 85–6, 88, 100–1, 102, 229–30, 231–2, 233–4, 237–8, 241, 250, 293–4, 299–300, 304
see also desmopressin; hemostasis
concepts 231–2, 237–8, 241, 250, 304
definition 232
factor VIIIa (VIIIa) 233
factor IX (FIX) 88, 102, 103, 147, 231, 232, 237–8, 239–40, 293–4, 299–300, 304
concepts 232, 237–8, 239–40, 304
definition 232
factor IXa (FIXa) 233
factor X (FX) 88, 103, 147, 231–3, 239, 299–300
concepts 88, 103, 147, 231–3, 239
definition 233
factor Xa (FXa) 233
factor XI (FIXI) 141, 147, 231, 233, 299–300
concepts 141, 147, 231, 233
definition 233
factor Xla (FIXla) 233
factor XII (FXII) 145, 299–300
factor XIII (FXIII) 90, 91, 101, 104, 147, 231, 232–3, 299–300
see also recombinant human FXIII
concepts 90, 91, 101, 104, 147, 231, 232–3
definition 232–3
Fanconi anemia 59
Fantus, B. 4, 201–2
Farhaeus effect 11
see also hematocrit levels
favism 141
FEIBA see factor eight inhibitor bypassing activity
fentanyl, controlled hypotension 194–5
ferroportin 38–41
ferrous/ferric switches, iron 36, 37–42
fetal erythroblastosis 234
fetal hemoglobin 224, 236–7
FFP see fresh frozen plasma
fibrin sealants 90–1, 217–18, 293
see also hemostasis; tissue adhesives/sealants (glues)
fibrinogen 3, 81, 91–5, 104, 120, 145, 218, 230, 231–2, 239, 248–9, 258, 299
see also plasma . . .
definition 232
fibrin sealants 91
surgery preparations 145
fibrinolysis 81–95, 196, 239
see also antifibrinolytics; hemostasis
blood management role 82–3, 196
physiology 82–3
fibronectin 231
Fick’s law of diffusion 10, 11
fidelity principle of ethics 286–7
filariasis 297
filgrastim 56–60
filters, cell salvage 213, 215, 217, 221, 223
filtration cleaning methods 215, 217, 221, 223, 247–9
finasteride 154
Finland 288
Fishbane reaction 40
flow (Q), oxygen delivery equation 9–10, 13–16, 17, 76–7, 112–13, 116, 129, 193–4, 251
flu epidemics 125–6
flu-like symptoms with bone pain, rHuEPO side effects 23–4
fluid management 67–79, 197–8, 303
see also colloids; crystalloids; intravenous fluids; plasma substitutes; volume therapy
absolute/relative/pathological fluid losses 68–9
administration methods 76, 197–8
anesthesia 197–8
blood loss goals 77–8
blood management influences 77–8
coagulopathy 69, 71, 75–8
compartments 69, 70
definition 67–9, 303
dose regimens 75–7
historical background 67–8
kidneys 69, 74–5
microcirculation 78
needs 68–9, 75–7
resuscitation considerations 75–8
trauma patients 77–8
types of solutions 69–74
usage guidelines 75–8
volume balance basics 69
fluorine, PFCs 109–10, 116–21
fluosol-DA 110, 117, 118
see also perfluorocarbons
fluoxetine 197–8
focused history taking, surgery preparations 140–4, 311, 324
folic acid 18, 26–8, 36, 44–5, 47–8
see also hematinics
Foley catheters 186
Fontaine’s mobile hyperbaric operating room 125
Food and Drug Administration (FDA) 294–5
forceps 178
formal one-to-one education, blood management programs 274, 277–8, 321
formalin, hemostasis 94
forms’ design, blood management programs 280–1, 321–2
four pillars of anemia 17–18
‘four-factor’ PCCs 231–2, 239
fractionation 229–41, 292–3
see also plasma fractions
Frank–Starling mechanism 67
free hemoglobin 111–16, 127–8, 217, 218, 219, 221–2, 248–9
see also hemoglobin . . .
free radicals 37–8, 127–8
fresh frozen plasma (FFP) 105, 230–2, 234, 237–40, 249–50, 257–8, 299
fulguration see desiccation
functional capillary density (FCD) 11–12, 15–18
see also microvasculature . . .
functional iron deficiency 39–43, 48
G-CSF see granulocyte-colony stimulating factor
Galen 174
galvanocautery 174–5
Gamow bags, hyperbaric oxygen therapy 133
garlic, coagulopathy effects 154, 311
gas laws 126–7
gastritis, surgery preparations 143
gastrointestinal tract 143, 146, 163–4, 168, 196, 198, 237–8, 252
gelatin uses 4, 68, 71–2, 73, 74–5, 92, 156, 217
see also colloids
definition 73, 92
historical background 4, 68
side effects 74–5, 92
gentle tissue handling, Halstedian principles 175
Germany 288–9
ginger, coagulopathy effects 154, 311
ginseng, coagulopathy effects 311
globins synthesis 36–7
see also hemoglobin
glucose 13–18, 70, 109–10, 145
glucose crystalloid solutions 70
glycoproteins 53, 56–64, 248–9
see also granulocyte-colony stimulating factor
glycosylation 101
GM-CSF see granulocyte–macrophage colony stimulating factor
good clinical practice aspects, blood management 1, 5–8
governments see also law
charters and bills 285–6, 287–91
initiators of blood management programs 263
granulocyte-colony stimulating factor (G-CSF) 53, 56–64, 163
see also white cells
clinical uses 58–9, 61–3
definition 53, 56
neutropenia 58
granulocyte–macrophage colony stimulating factor (GM-CSF) 52, 53, 56–64
see also white cells
clinical uses 58–9, 62–3
definition 53, 58
granulocytes 52–64, 218, 249–50, 257–8
concentrates 249–50, 257–8
transfusion guidelines 249–50, 257–8
Green Cross in Japan 110, 117
green tea 311
grid analysis, decision making 256, 258
Griswold and Ortner’s cell salvage case series 213
growth factors 51–66, 163
see also erythropoietin
blood management uses 61–3
cancer-progression possibilities 59–61
combinations 56, 58, 63
definitions 51
general concerns 58, 59–61
leukocytes 51–3, 56–60, 62–3, 163
multilineal hematological failures 63
multilineal pluripotent aspects 59–60, 63
neutropenia 58–64
platelets 53–7, 61–3
roles 51–3
side effects 58, 59–61
thrombocytopenia 61–3
transfusion alternatives 62
Guillain–Barré syndrome 236
gum solutions, colloids 68
gynecological surgery 195, 198, 213, 225, 270
Haemoglobin Color Scale 145
Haldane effect 10
halothane 197–8
Halsted, William Stewart 3, 126, 175
Halstedian principles 3, 175, 187
Hamlin 4
hamster kidney cells, recombinant blood products 23, 101, 104
Handler, Seymour 273
haptoglobin 221–2, 248–9, 300
harmonic scalpel 175
Hartmann, Alexis 68, 70
Hartmann’s crystalloid solution 70
HAS-BLED scores 165
HBmin see minimum tolerable hemoglobin
HBOC-201 114, 119
HBOCs see hemoglobin-based oxygen carriers
HBV see hepatitis B
HCV see hepatitis C
head and neck surgery, positioning factors 193
heart
adaptation mechanisms to anemia 14–18
macrocirculatory adaptations to anemia 14–15
oxygen extraction ratio 13, 250, 302
surgery preparations 143, 154
heart rate (HR), oxygen delivery equation 9–11, 13–14, 17, 112–13, 116, 129
heat uses in surgery 173, 174, 176–9
see also physical methods of hemostasis
helper T lymphocytes 253
see also Th . . .
hematide (peginesatide), erythropoiesis-stimulating agents 30, 31
hematinics 26–8, 36–50, 150–1, 311, 313, 317
see also cobalt; copper; folates; iron . . .; nicotinic acid; riboflavin; vitamin . . .; zinc
anemia treatments 47–9
antibiotics 47
blood loss due to medical/surgical interventions 47–8
blood management role 36, 37–49
definition 36
EPO hyporesponsiveness 26–7, 47
EPO therapy 26–7, 47
iatrogenically-induced deficiencies 26–7, 47–8
indications 36, 37–47
interactions 47, 48
physiological issues 36–7
primary prevention of anemia 47–8
psychotherapeutic drugs 48
rHuEPO 26–8
 Index 339


see also Ig . . . ; plasma . . .

administration 235

avian antibodies 105
definition 234–5
functions 234–5, 241
HBOCs 114
normal/
hyperimmunoglobulins 235–7
recombinant blood products 101, 105, 230
side effects 235–6

immunosuppression problems 5, 24–5, 143, 219, 235–7, 253
India 2–3
indirect cell salvage 212–17, 218, 219–25

see also cell salvage

INDs see investigational new drugs

induced hypotension see controlled hypotension
infections
see also hepatitis . . . ; HIV/AIDS; leukocytes; malaria; syphilis
EPO hyporesponsiveness 26
HBOCs 113–14
oxygen consumption 13
surgery preparations 149
inflammation 26, 29, 39, 234–7
inflammatory bowel disease, rHuEPO therapy 29
informal business proposals, blood management programs 264–5
informal one-to-one education, blood management programs 274
information
detailed information 297–304
informed consent 277, 282, 286, 288–9, 295, 313, 316–17, 318
see also autonomy principle of ethics definition 286, 288
errors 282
exceptions 289
Jehovah’s Witnesses 293
minors 290, 318
infrared contact coagulator 179
inhalational oxygen therapy 124–36
see also oxygen therapy
blood management uses 134–6
contraindications 129–30
definition 124, 129–30
diagnostic measures 130
duration considerations 132
historical background 124–6
indications 129–30
oxygen delivery systems 131
practical recommendations 131–2
side effects 131–2
technical background 130–1
initial analysis, blood management programs 263–4, 267, 270–1, 310–12
initiators of blood management programs 262–4, 267–8, 269–70
Innocent VIII, Pope 246
inotropics, anemia treatments 17–18
inspiratory oxygen fraction (FiO2) 10, 126–9, 130–6, 206
insulin
FVIII release 82
rHuEPO 24–5
interferons 57, 62, 151, 253
see also cytokines
interleukins 51–64, 217, 218, 253
see also cytokines; IL . . .
intermittent (discontinuous) blood washing, cell salvage 215–16, 218, 219–21
international normalized ratio (INR) 145, 152–4, 169–70, 250–1
International Standards Organization (ISO) 271
interstitial fluids (ISF) 69–79
interval training, physical exercise 163
intracellular fluids (ICF) 69–79
intravenous fluids 17–18, 67–79
intravascular fluids (IVF) 69–79
intraoperative cell salvage 212–26
see also cell salvage
intraoperative hyperoxic ventilation, oxygen therapy 135
intravascular fluids (IVF) 69–79
intravenous fluids 17–18, 67–79
see also fluid management allergic reactions 73, 75
anemia treatments 17–18
basics 69
dose regimens 75–7
hemostasis impairments 74
historical background 67–8
hyperchloremic metabolic acidosis 68, 75, 222
side effects 71, 73–5, 77–8
types 69–74
intravenous immunoglobulins of human origin (IVIGs) 236, 238, 240–1
investigational new drugs (INDs) 285, 294–5, 317
see also compassionate use; ethics
ion gradients, adaptation mechanisms to anemia 17–18
iron 18, 21, 25–32, 36–41, 47–8, 113–14, 144, 163
see also hematinics
absolute/functional deficiencies 39–43, 48
absorption from the intestine 39–40
anemia treatments 18, 21, 25–32, 36, 48
blood management role 37–41
cancer-progression possibilities 38–9
copper 41–3
deficiencies 39–43, 47, 48
definition 36
EPO hyporesponsiveness 25–6
ferrous/ferric switches 36, 37–42
free radicals 37–8
HBOCs 113–14
hepcidin 38–41
liver 38–9
macrophages 38–9, 41
markers of iron deficiency 40–3
overload problems 25–6, 37–8, 46, 255
physiology 37–41
regulation processes 38–9
storage/reuse processes 38
thresholds 38, 40
vitamin C 39–40, 48
iron dextran 40, 68, 70
iron gluconate 40–1
iron sucrose 40–1, 48
iron therapy 21, 25–32, 39–41, 48, 163, 203
concepts 39–41, 48, 163, 203
dose regimens 40
intravenous administration 40–1
oral administration 39–41
PADs 203
preparations 39–41
rHuEPO 21, 25–32
iron-containing formulas, historical background 2–3
ischemic heart disease, transfusion risks 252
ISF see interstitial fluids
ISO see International Standards Organization
isoflurane 194–5, 197
isogenic transfusions see allogeneic transfusions
ITP 61–3, 237
IVF see intravascular fluids
IVIGs see intravenous immunoglobulins of human origin

Jacobs et al 21
Jakarta Declaration on Health Promotion into the 21st Century (1997) 288
Jehovah’ Witnesses 1–3, 5, 6, 263, 265, 285, 291–5, 317
see also Hospital Liaison Committees; religions
attitudes to medical care 291–3
‘closed circuit’ considerations 292–3
HIS 294–5
historical background 1–3, 5, 6
HLCs 2, 294–5
informed consent 293
initiators of blood management programs 263, 265
law 2, 285, 294–5
lifestyles 291–2
list of accepted/unaccepted blood products 293
physicians 263, 292–5
PVG 294–5
The Watchtower 2, 293–4, 308
Jennings, C. 4
John Hopkins 3
journal clubs, education 275–6
justice principle of ethics 286, 287

kallikrein 82
Kawasaki disease 236
Kay, Jerome 2
KEM Hospital in Mumbai, India 2
Kennedy, John F. 287
keratin 78
Keynes, John Maynard 246
see also erythropoietin
anemia etiology 21, 28–9, 256
cell salvage 221–2
colloids 74–5
fluid management 69, 74–5
HBOCs 113
oxygen extraction ratio 13, 250
pathophysiology of anemia 13–18, 28–9
surgery preparations 142–3, 151–4
transfusion risks 252
kinetic energy in surgery 181
see also physical methods of hemostasis; water jets
Klebanoff, Gerald 3–4, 213, 214
knee surgery 186–7, 193, 195, 198
Kraut et al 82
Krogh model of tissue oxygenation, concepts 11–12
Kunitz et al 82
L-carnitine 26–8, 46
labelled bags/bottles 220, 247
laboratory personnel, education 272–8
laboratory tests 140, 144–5, 147, 160–3
see also phlebotomy; surgery preparations
lactate 13–18, 68, 70, 119, 146, 250
Lancet 125
Langmuir, Irving 175
Lanthin, Ron 2–3
lasers 175, 179–80
see also light . . . ; physical methods of hemostasis
Latham, Allen ‘Jack’ 213, 215–16
Latham bowl 215–17, 219
Latta, Thomas 67–8
law 2, 6–7, 270–1, 272, 273, 282–3, 285–96, 318, 323–4
see also bills; charters; ethics; principles; rights
administration of blood management programs 6–7
advance directives (living wills) 289, 295
definition 287–8
Jehovah’ Witnesses 2, 285, 294–5
lecithin 109, 116–20
lectures and grand rounds, blood management programs 274
LEH see liposome-encapsulated hemoglobin solution
leishmaniasis 298
lenograstim 56–60
leukemia 48, 58–9, 61–2, 224
see also eosinophils; lymphocytes; neutrophils
leukopoiesis 52–3, 163
see also white cells
ligature of vessels, historical background 174
light in surgery 175, 179–80
see also infrared contact coagulator; lasers; physical methods of hemostasis
Lin et al 21
lineage steal concerns, growth factors 59–61
Linton–Nachlas tubes 186
lips 248–9
liposome-encapsulated hemoglobin solution (LEH) 112, 114–15, 120
liquid oxygen, oxygen therapy 130–6
Listeria monocytogenes 298
literature articles, education 276, 305–8
litigation fears 273
liver 13–18, 21–2, 28–9, 38–9, 62, 82–5, 87–8, 142–4, 147, 181, 182–3, 185–6, 196–7, 232–4, 239, 241, 288, 311
see also plasma . . .
anesthesia 196–7
bleeding in coagulopathies 239
cardiac output share 182
coaagulation problems 142–3
disease symptoms 144, 147
EPO production at birth 21–2, 28–9
fibrinolysis 82–5
iron 38–9
mesh wraps 185–6
pathophysiology of anemia 13–18
surgery preparations 142–4, 147
thrombocytopenia 62
vasculcar occlusion 182–3
Ljubljana Charter on Reforming Health Care (1996) 288
local hemostatic agents 4, 81–2, 89–95
see also hemostasis; tissue adhesives . . . ; vasoconstrictors
Lundy, J.S. 4–5, 7, 246
lungs 10–20, 126–7, 143, 178–9, 254
adaptation mechanisms to anemia 15–18
gas laws 126–7
red blood cells 10–20
surgery preparations 143, 178–9
lymphocytes
see also B . . . ; natural killer cells; T . . . ; white cells
concepts 51–3, 56–60, 235–8, 253
lysine derivatives 3–5, 56–60, 235–8, 253
see also antifibrinolytics
M-CSF see monocyte colony stimulating factor
macrocirculation
see also oxygen delivery
anemia adaptation
mechanisms 14–15
concepts 9–20, 68–79
definition 9–10
oxygen delivery equation 9–10, 13–14, 17, 129
macrodex 68
macrophages 38–9, 41, 52–3, 56–64, 235–7, 253
see also granulocyte–macrophage . . . ; monocytes; phagocytosis
magnesium ions 70
magnetic resonance imaging (MRI) 150
major histocompatibility complex (MHC) 253
Makuuchi’s maneuver, vascular occlusion 182–3
malaria, transfusions 2, 298
Mallory–Weiss tears 186
MANAGER usage-reduction mnemonic, plasma fractions 240–1
manual compression 184
Marfan syndrome 143
market research 262
marketing
advertising restrictions 282–3, 314, 316–19
blood management programs 262, 278, 282–3, 316–19
clubs 278
definition 262, 278
media choices 278, 282–3, 318–19
tools 278, 318–19
mast cells 52
mature minor rule 290, 318
MB-FFP 250
MCHC 41
MDS see myelodysplasia
mean cell volume (MCV) 41, 146
MECC see minimized extracorporeal circulation
mechanical ventilation 17–18, 164, 196–7, 250–2
media choices, marketing 278, 282–3, 318–19
medical organizations, blood management 5, 305–8
medications
see also blood-derived pharmaceuticals; treatments
anesthesia regimens 197
common anticoagulants 152–3, 205–6, 209, 218, 220–1, 233–7
controlled hypotension 194
educational samples of equipment/drugs 277
hemolytic drugs 18, 236–7
iatrogenic blood loss 160, 165, 169
surgery preparations 144, 154–5
systemic hemostatic drugs 81–9, 151–4, 311
meetings, blood management programs 269–70, 321
megakaryocytes 51–64
melatonin, erythropoiesis-stimulating agents 31, 32
meperidine 197–8
mesh wraps, compression concepts 185–6
Messmer, Konrad 202
methemoglobin 247–9
metoclopramide, erythropoiesis-stimulating agents 31
meperidine 197–8
mesh wraps, compression concepts 185–6
MINDEC decision-making mnemonic 251–8
microporous polysaccharide hemisphere, tissue adhesives/sealants (glues) 93
microsampling methods, phlebotomy 161–2
microvasculature in the tissue see also capillaries; functional capillary density
red blood cells 11–12, 15–18, 72–3, 112–13, 134–5
microwave tissue coagulator 175, 179
microwaves in surgery 175, 179
see also physical methods in hemostasis
Middendorf, Albrecht Theodor 174
military influences 1, 3–4, 110, 184, 213
milk infusions, historical background 4, 67–8
mineral zeolite, tissue adhesives/sealants (glues) 93
minerals 36–49
see also hematinics; individual mineral
minimized extracorporeal circulation (MECC) 167–8
minimum tolerable hemoglobin (HBmin), surgery preparations 140, 148–56
minors, patients’ rights 290, 318
mitochondria 12–13, 16–18, 36–8, 41–3, 46
see also oxygen consumption
Miyake et al 21
mobile hyperbaric chambers 125, 133
molecular weights, colloids 67, 72
moles/molality/molarity, definitions 303
molgramostim 58–60
monocyte colony stimulating factor (M-CSF) 59
monocytes 24–5, 52–3, 56–60
see also macrophages
monoplex chambers, hyperbaric oxygen therapy 132–3
Monsel’s solution, hemostasis 94
morpheine 194
see also opioids
mortality rates
anemia 21, 256, 287
fluid management goals 68–9, 77–8
hypothermia 196, 205
transfusions 4, 252, 256, 287
motivation needs, blood management programs 263–4
MRI see magnetic resonance imaging
mRNA 249
mucosa 83, 163–4, 241
multidisciplinary approaches 1, 6–8
multilinear hematological failures, growth factors 63
multimodal approaches 1–8, 208, 270–1
multiplace chambers, hyperbaric oxygen therapy 132–3
muscle relaxants 197
musculoskeletal disorders, surgery preparations 142–3
myelodysplasia (MDS), growth factors 58–9, 62, 63
myelopoiesis 52–3
see also granulocytes; monocytes
myocardial infarction 250–2
myocardium, oxygen consumption 13, 14, 127, 134–5, 256
myoglobin-facilitated oxygen diffusion, concepts 13

naftazone, hemostatic drugs 89
Nagelschmidt, Franz 174
nandrolone, anemia treatments 31, 32
naphthoquinone ring structure 81, 86–8
see also vitamin K
nartograstim 58–60
National Institutes of Health 5
natural killer cells 219, 253
neodymium lasers 180
neonatal anemia, cord-clamping delay benefits 168
neonatal thrombocytopenia 62
NESP see novel erythropoietin-stimulating protein
Netherlands 288
neurological system review, surgery preparations 143
neutrophils 52–3, 55–6, 62–3, 71, 127–8, 219, 234, 251
niacin 46
nicotinic acid 36
see also hematinics
nitric oxide 12, 13, 15–16, 78, 105, 111, 113, 221–2, 234, 247–9
nitrogen 126–36
nitrinous oxide 197–8
non-governmental organizations (NGOs), charters and bills 285–6, 287–91
non-maleficence principle of ethics 286–7, 289, 291, 295
non-peptide TPO agonists 55
see also eltrombopag
non-rebreathing masks, inhalational oxygen therapy 130–6
norepinephrine 94
norethisterone 88
normal physiology, oxygen transport 9–13, 116, 126–7
normobaric oxygen paradox 129
nothing-done decisions, BRAND decision-making mnemonic 247, 256, 258
novel erythropoietin-stimulating protein (NESP) 30, 32
NSAIDs 144, 154, 165
see also aspirin
nurses see also iatrogenic blood loss; physicians
blood management programs 6–7, 262–82, 309–22
education 7, 154, 162–3, 262–4, 269, 271–8
initiators of blood management programs 263
nutrition 18, 143–4, 154
see also hematinsics
obliterative coagulation 173
octocog, recombinant FVIII 102
ocular effects, oxygen 128
oncotic effects, HBOCs 112
open heart surgery 2
opioids 197
see also morphine
oral presentations, blood management programs 264–5
ORS see oxidized regenerated cellulose
Orejola, Wilmo 175
osmolality/osmolarity, definitions 303
osmotic pressure, definition 303
O’Shaughnessy and Brooke 67
Oster, William 125
Oster–Rendu–Weber disease 88
osmoregulation 303
O2 ER see oxygen extraction ratio
Ottenberg, Reuben 4
outcome risk factors, transfusions 250–2, 280
overdraw problems, iatrogenic blood loss 161–2, 168–9
oxalic and malonic acids, hemostatic drugs 88–9
oxidative damage, HBOCs 114–15, 252
oxidized regenerated cellulose (ORC), tissue adhesives/sealants (glues) 92–3
oxyctye 117
oxygen 9–10, 109–21, 124–36, 218–19
cell salvage 218–19
cerebral effects 128
circulatory effects 127
dangers 127
gas laws 126–7
hematological effects 128–9
hemoglobin 9–10, 109–21
historical background 124–6
immune system 127–8
metabolic effects 128
ocular effects 128
physics 126–7
physiology 126–9
pulmonary effects 128
side effects 124, 127–9, 132, 134
toxic effects 128–9
water 126–7, 302
oxygen affinity, HBOCs 112, 113
oxygen availability increase therapies 9–20
oxygen consumption (VO2) 9–20, 118–20, 302
see also mitochondria
oxygen delivery relationship 17–18, 76–7, 118, 302
temperature factors 13
see also macrocirculation; microcirculation
anemia treatments 17–18, 130–6
oxygen consumption relationship 17–18, 76–7, 118, 302
oxygen dissociation curve 12–13, 16–18, 116, 247–9
oxygen extraction ratio (O2 ER) 13, 14–15, 16–18, 250, 302
oxygen give-up and tissue take-up processes 12–13, 16–18, 36–7, 110–11, 116–20, 247–9
oxygen mixing, oxygen therapy 130–6
oxygen saturation of hemoglobin (SaO2) 9–10, 12–13, 16–18, 129–36, 162, 251–8, 302
anemia treatments 17–18
oxygen delivery equation 9–10, 13–14, 17, 116, 129–30, 251, 302
oxygen solubility in plasma, oxygen delivery equation 9–10, 13–14, 17, 116, 129, 302
oxygen supply, oxygen therapy 130–6
oxygen take-up processes, red blood cells 10–11, 15–18, 110–11, 116–20, 247–9
oxygen tents, inhalational oxygen therapy 131–2
oxygen therapy 124–38, 164, 313
see also hyperbaric ... ; inhalational ... administration 124, 125–6
blood loss treatments 124, 136
blood management uses 134–6
contraindications 129–30, 132
diagnostic measures 132
duration considerations 132
erythropoiesis stimulation 136
free radicals 127–8
historical background 124–6
indications 129–30, 132
intraoperative hyperoxic ventilation 135
sickle cell disease 135
side effects 124, 127–8
historical background 124–6
indications 129–30, 132
intraoperative hyperoxic ventilation 135
partial re-breathing masks, inhalational oxygen therapy 131–2
participation rights 287–90
parvovirus B19 infection 236, 298
patient blood management see also blood management
definition 1, 3, 5
patient education benefits 154, 163, 272
patient selection issues, rHuEPO 28–30
patient-centric approaches 1–8, 154, 246–58, 271–2
patient-visit-in-group (PVG) 294–5
see also Jehovah’ Witnesses
see also ethics; law; principles; religions
advance directives (living wills) 289, 295
definition 285, 287–8
historical background 2–3
Jehovah’ Witnesses 1–3, 5, 6, 285, 291–5
minors 290, 318
pregnancy and motherhood 289–90, 318
refusal of treatments 289–91, 318, 323–4
PCCs see prothrombin complex concentrates
Pearse, Dr 2
PEEP see positive end-expiratory pressure
peer reviews and audits, education 274, 275, 277–8, 312
PEG-rHuMGDF see pegylated recombinant human megakaryocyte growth and development factor
pegfilgrastim 56–60
pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) 54–5, 61–2, 114–16
Pelet 174
Penfield’s work 68
penicillins 154, 165, 238
Penrose drain 186
peptic ulcers 143, 163–4, 169
peptide TPO-R agonists 55
see also romiplostim
peptides 38–9, 120
perfluorocarbons (PFCs) 109–10, 116–21, 293–4
see also artificial blood characteristics 116–17
definition 109, 116
dose regimens 116
half-life 116, 120
historical background 110
oxygen delivery 116–18
perfloran 117
perioperative apheresis 201, 202, 208–9, 239–40, 247, 249
see also autologous blood; plasma-apheresis; platelet-apheresis
PFCs see perfluorocarbons
pH 12–13, 16–18, 38, 92–3, 162, 249, 250
phagocytosis 53, 59–61, 127–8, 234–7
see also granulocytes; macrophages; monocytes
pharmaceuticals 229–44
see also blood-derived pharmaceuticals; medications
pharmacological hemostasis 3
phenylephrine 94
phenytoin 238
phlebotomy 144, 151, 160–3, 168–70, 317
see also iatrogenic blood loss; laboratory tests
‘bloodless’ monitoring alternatives 162–3
dead space volume 161–3, 168–70
education 162–3
historical background 160–1
microsampling methods 161–2
necessity assessments 161–2, 168–9
point-of-care devices 161–2, 317
problems 160–1
records 162
reduction of blood losses 161–3, 168–9
sampling sites 162
phosphate 13–18, 151, 205–6, 209, 213, 220–1, 248–9
phosphorus 151
phosphorylation 101

Index  343

oxygen take-up processes, red blood cells 10–11, 15–18, 110–11, 116–20, 247–9
oxygen tents, inhalational oxygen therapy 131–2
oxygen therapy 124–38, 164, 313
see also hyperbaric ... ; inhalational ... administration 124, 125–6
blood loss treatments 124, 136
blood management uses 134–6
contraindications 129–30, 132
diagnostic measures 132
duration considerations 132
erythropoiesis stimulation 136
free radicals 127–8
historical background 124–6
indications 129–30, 132
intraoperative hyperoxic ventilation 135
sickle cell disease 135
side effects 124, 127–8
historical background 124–6
indications 129–30, 132
intraoperative hyperoxic ventilation 135
partial re-breathing masks, inhalational oxygen therapy 131–2
participation rights 287–90
parvovirus B19 infection 236, 298
patient blood management see also blood management
definition 1, 3, 5
patient education benefits 154, 163, 272
patient selection issues, rHuEPO 28–30
patient-centric approaches 1–8, 154, 246–58, 271–2
patient-visit-in-group (PVG) 294–5
see also Jehovah’ Witnesses
see also ethics; law; principles; religions
advance directives (living wills) 289, 295
definition 285, 287–8
historical background 2–3
Jehovah’ Witnesses 1–3, 5, 6, 285, 291–5
minors 290, 318
pregnancy and motherhood 289–90, 318
refusal of treatments 289–91, 318, 323–4
PCCs see prothrombin complex concentrates
Pearse, Dr 2
PEEP see positive end-expiratory pressure
peer reviews and audits, education 274, 275, 277–8, 312
PEG-rHuMGDF see pegylated recombinant human megakaryocyte growth and development factor
pegfilgrastim 56–60
pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) 54–5, 61–2, 114–16
Pelet 174
Penfield’s work 68
penicillins 154, 165, 238
Penrose drain 186
peptic ulcers 143, 163–4, 169
peptide TPO-R agonists 55
see also romiplostim
peptides 38–9, 120
perfluorocarbons (PFCs) 109–10, 116–21, 293–4
see also artificial blood characteristics 116–17
definition 109, 116
dose regimens 116
half-life 116, 120
historical background 110
oxygen delivery 116–18
perfloran 117
perioperative apheresis 201, 202, 208–9, 239–40, 247, 249
see also autologous blood; plasma-apheresis; platelet-apheresis
PFCs see perfluorocarbons
pH 12–13, 16–18, 38, 92–3, 162, 249, 250
phagocytosis 53, 59–61, 127–8, 234–7
see also granulocytes; macrophages; monocytes
pharmaceuticals 229–44
see also blood-derived pharmaceuticals; medications
pharmacological hemostasis 3
phenylephrine 94
phenytoin 238
phlebotomy 144, 151, 160–3, 168–70, 317
see also iatrogenic blood loss; laboratory tests
‘bloodless’ monitoring alternatives 162–3
dead space volume 161–3, 168–70
education 162–3
historical background 160–1
microsampling methods 161–2
necessity assessments 161–2, 168–9
point-of-care devices 161–2, 317
problems 160–1
records 162
reduction of blood losses 161–3, 168–9
sampling sites 162
phosphate 13–18, 151, 205–6, 209, 213, 220–1, 248–9
phosphorus 151
phosphorylation 101
physical activities, oxygen consumption 13
physical examinations, surgery preparations 144
physical exercise
anemia 154, 163, 252
resting patients 163
surgery preparations 154
types 163
physical methods of hemostasis 3, 173–90, 313
see also compression; electrical currents . . . ; hemostasis; scalpels; selective occlusion of vessels; surgery . . .
drains 186, 192–3, 208
Halstedian principles 3, 175, 187
heat uses 173, 174, 176–9
historical background 173–5
kinetic energy in surgery 181
light in surgery 175, 179–80
microwaves in surgery 175, 179
plasma gas uses 175, 176–9
positioning factors 187, 192–3
tourniquets 4, 81–2, 155, 174–5, 183–4, 313
vibration uses in surgery 181–2
physically dissolved oxygen in blood 10–20, 126–7
physicians
see alsoiatrogenic blood loss; nurses; principles
algorithms 4, 139–40, 145–6, 155, 168, 256, 270–1, 275, 305–7, 311–13, 317–18
blood management programs 6–7, 262–82, 309–22
compassionate use 285, 294–5, 317
consience 290–1
education 7, 154, 162–3, 262–4, 269, 271–8
initiators of blood management programs 263, 269–70
Jehovah’s Witnesses 263, 292–5
variable practices 7, 246–7, 279
physiology of anemia 9, 13–20
placenta 198, 236–7, 240
see alsoalbumin; coagulation . . . ; immunoglobulins
consituents 230–1, 247–50, 292, 300
detailed information 300
storage guidelines 249–50
plasma fractions 229–41, 292–3
see also blood-derived pharmaceuticals
blood loss avoidance 240–1
definition 229, 230
historical background 229–30
MANAGER usage-reduction mnemonic 240–1
other less safe products 239–40
side effects 239–40
plasma gas 175, 180–1
see also physical methods of hemostasis
plasma scalpels 175, 180
plasma substitutes 3–4, 67, 71–9
see also colloids; fluid management
definition 67, 71
historical background 3–4, 67–8
plasma-derived comparisons, recombinant blood products 101–2, 106, 241
plasma-pheresis 6, 24–5, 166–7, 201, 208–9, 239–40, 247–9, 257–8, 313
see also blood-derived pharmaceuticals
plasmin, antifibrinolytics 81–5
plasminogen 81–5, 300
platelet anesthesia 167
platelet-pheresis 6, 24–5, 166–7, 201, 208–9, 239–40, 247–9, 257–8, 313
see also autologous blood
critique 208–9, 257–8
definition 201, 208–9
platelet/platelet sequestration 201, 208–9
see also autologous blood
concepts 201, 208–9
critique 208–9
definition 201, 208–9
platelet-poor plasma (PPP) 208, 215–16
television substitutes (PRP) 208, 215–16
platelet-rich plasma (PRP) 208, 215–16
platelets 6, 24–5, 51–64, 81–95, 103, 109, 120, 143, 147, 151, 165, 166–8, 196–8, 201, 215–17, 248–9, 257, 292–4
anesthesia 196–8
ANH 206–8
artificial platelet substitutes 109, 120
complexities 120
concentrates 249, 257
counts 145, 147, 151, 163, 165, 196, 217–18, 250–2, 257
definition 120
growth factors 53–7, 61–3
maturation processes 51–3
rHuEPO 24–5
storage guidelines 249
surgery preparations 143–5, 147, 151
tissue healing 89–95
transfusion alternatives 62
transfusion guidelines 249, 257
Plummer Vision syndrome 141–2
pneumonia 293
point-of-care devices, phlebotomy 161–2, 317
policies and procedures, blood management programs 6–7, 262, 270–82, 305–7, 315–17
polychromatophilic erythroblast, erythropoiesis 22–32
polycythemia, preoperative treatments 150–1
polymerization, free hemoglobin 111–14
polymersome encapsulated hemoglobin (PEH) 112–13
polyvinylpyrrolidone (PVP) 68–9, 78
The Pope, transfusion bans 4
positioning factors
anesthesia 192–3
head and neck surgery 193
physical methods of hemostasis 187, 192–3
spinal surgery 193
surgery 187, 192–3, 313
positive end-expiratory pressure (PEEP) 196–7
postoperative anemia, ANH effects 208
postoperative cell salvage 212–26
see also cell salvage
potassium 70, 218
PPP see platelet-poor plasma
PRCA see pure red cell aplasia
anti-D-immunoglobulin 236–7, 240
BRAND decision-making mnemonic 252
cell salvage 212–14, 224
cord-clamping delay benefits 168
fetal hemoglobin 224, 236–7
hematinic deficiencies 47
Index

PADs 202, 204
patients’ rights 289–90, 318
rHuEPO therapy 28, 32
surgery preparations 145
vitamin K 87
preoperative anemia management 3, 139–56, 166–8
preoperative autologous donations (PADs) 201, 202–4, 206–7, 253, 292
see also autologous blood
contraindications 202
costs 203, 204, 207
critique 203–4, 207, 253
definition 201, 202, 292
eligibility criteria 202, 204
historical background 201–2
risks 203–4, 207, 253
side effects 203–4
theoretical basis 202–3
preoperative blood management, concepts 3, 139–56, 166–8
preoperative work-up of accompanying disorders, surgery preparations 145
preoperative work-up of anemia, surgery preparations 144–5
preoperative work-up of impaired clotting, surgery preparations 145–7
preparation
see also surgery preparations
definition 139
preparing the equipment, surgery preparations 154–6
preparing the patient, surgery preparations 140, 150–4
presentations, blood management programs 264–5
‘pressure sore anemia’ 163
prewarming, anemia treatments 17–18
Priestley, Joseph 125
primum nihil nocere 286
see also beneficence principle of ethics
see also bills; charters; ethics; law; religions; rights
the Bible 285, 291–4
pyridoxine 285–6
Pringle maneuver, vascular occlusion 182–3
priority-setting processes, blood management programs 279, 281
problems and requirements analysis, blood management programs 262, 264, 265, 278, 279, 281, 320
procedural choices, anesthesia 197–8
procoerin 87
proerythroblast, erythropoiesis 22–3
programs 1, 2–3, 5, 6–7, 262–84
see also blood management programs
bloodless programs 2–3, 5
definition 262
progress-monitoring methods
blood management programs 265–6, 273, 281–2
education 272, 273
prolactin, erythropoiesis-stimulating agents 31
propofol 13, 194–5, 197
prospective reviews, education 275
prostate cancer 31, 154, 181, 195
protein C 231, 233–4, 239, 250, 299–300
protein S 231, 239, 250
proteins
see also albumin; hemoglobin
cell salvage 218
cryoglobulins 230–1
detailed information 301
heat in surgery 176
plasma fractions 229–41
red blood cell concentrates 248–50, 301
prothrombin 87, 88, 167–8, 230, 231–3, 258
prothrombin complex concentrates (PCCs) 231–2, 238–40, 258, 299
proton pump inhibitors 164
Providence Sunday Journal 3
PRP see platelet-rich plasma
psychotherapeutic drugs, hematinics 48
pulmonary functions
oxygen 128
surgery preparations 154, 207–8, 217, 250–1
pure red cell aplasia (PRCA) 24–5, 236
purines 36–7, 45
PVG see patient-visiting group
pyridoxine 46, 112
see also vitamin B6
pyrimidines 36–7, 45
Quick uses, surgery preparations 145, 147, 152–4
Quincke’s disease 234
R (relaxed) form hemoglobin 12
Rabiner’s treatment 110
radiation therapy 61–3, 270
radiofrequency ablation 178–9
see also electrical currents for surgery; physical methods of hemostasis
random donor platelet concentrates 249
RBC loss estimates during surgery 148–9
RBCs see red blood cells
reading assignments, education 275–6
receptors
EPO 22–32, 52–3
growth factors 22–32, 52–64
recombinant blood products 21–32, 39, 44, 47, 63, 100–8, 110–11, 116, 150–1, 230, 241, 293–4, 317
basics 101–2
blood management uses 102–5, 230
costs 26, 31, 102
definition 23, 100
excess demands 110–11
historical background 21, 100–1
plasma-derived comparisons 101–2, 106, 241
production processes 23, 101, 104–5
side effects 101–2, 106
sources 23, 101, 105, 110–11
recombinant form of human M-CSF (rHuM-CSF) 59
recombinant human antithrombin (rHuAT) 104–5, 299
recombinant human erythropoietin (rHuEPO) 21–32, 39, 44, 47, 63, 141, 150–1
see also erythropoietin
adjuvant therapies 21, 26–32
athletes 28
biosimilars 23
costs 26, 31
definition 23
dose regimens 23–4
effects not directly related 25
EPO alpha/beta/omega forms 23
half-life 23, 30
historical background 21
indications 28–30
iron therapy 21, 25–32
patient selection issues 28–30
prevention indications 28
production processes 23
risk–benefit ratio 25–32
side effects 23–5, 47
types 23
Index

recombinant human FVIIa (rHuFVIIa) 4, 103–4, 106, 156, 231–2, 237–9, 258, 299
dose regimens 104
side effects 104
recombinant human FVIII (rHuFVIII) 102, 304
recombinant human FXIII (rHuFXIII) 101, 104
recombinant human hemoglobin (rHuHb) 100, 105, 113
recombinant human interleukin-11 (rHuIL-11) 56–7, 61–3
recombinant human serum albumin (rHuSA) 100, 101, 105, 116
recombinant human TPO (rHuTPO) 54, 61–3

records
administration of blood management programs 6–7, 279–81, 310–12
phlebotomy procedures 162
rectal muscle fragment welding 177
see also anemia; erythropoiesis; hemoglobin
anemia pathophysiology 9, 13–20
BRAND decision-making mnemonic 247, 250–8
capillaries 11–12, 15–18, 118, 251–8
carbon dioxide 10–11, 12–13, 15–18, 129
cell salvage 215–26
concentrates 247–9, 251–8, 301
constituents in stored concentrates 248–9, 301
deformability abilities 11, 247–9, 251–2
guidelines 247–9, 256–8, 305–7
hemodilution 204–8
hyperbaric oxygen therapy 126–36
journey through the body 10–13, 14–18, 116–18
lungs 10–20
microvasculature in the tissue 11–12, 15–18, 72–3, 112–13, 134–5
oxygen give-up and tissue take-up processes 12–13, 16–18, 36–7, 110–11, 116–20, 247–9
oxygen take-up processes 10–11, 15–18, 110–11, 116–20, 247–9
PADs 202–4
proteins in concentrates 248–50, 301
RBC loss estimates during surgery 148–9
resting patients 160, 163
spacing factors 16
storage guidelines 247–9
transfusion risks 247, 250–8

Résumé
administration of blood management programs 6–7, 279–81, 310–12
phlebotomy procedures 162
rectal muscle fragment welding 177
see also anemia; erythropoiesis; hemoglobin
anemia pathophysiology 9, 13–20
BRAND decision-making mnemonic 247, 250–8
capillaries 11–12, 15–18, 118, 251–8
carbon dioxide 10–11, 12–13, 15–18, 129
cell salvage 215–26
concentrates 247–9, 251–8, 301
constituents in stored concentrates 248–9, 301
deformability abilities 11, 247–9, 251–2
guidelines 247–9, 256–8, 305–7
hemodilution 204–8
hyperbaric oxygen therapy 126–36
journey through the body 10–13, 14–18, 116–18
lungs 10–20
microvasculature in the tissue 11–12, 15–18, 72–3, 112–13, 134–5
oxygen give-up and tissue take-up processes 12–13, 16–18, 36–7, 110–11, 116–20, 247–9
oxygen take-up processes 10–11, 15–18, 110–11, 116–20, 247–9
PADs 202–4
proteins in concentrates 248–50, 301
RBC loss estimates during surgery 148–9
resting patients 160, 163
spacing factors 16
storage guidelines 247–9
transfusion risks 247, 250–8

riboflavin 36, 45, 47–8, 114
see also hematinics
rickettsia 297, 298
right to know principle of ethics 286–7
see also bills; charters; consumer . . . ; ethics; human . . . ; patients’ . . . ; principles
definition 285–6, 287–8
historical background 287
Ringer, Sydney 68, 70
Ringer’s crystalloid solution, concepts 70, 78, 221
risk–benefit ratios
see also individual topics
allogeneic transfusions 245, 246, 250–2, 291
BRAND decision-making mnemonic 247, 251–5, 258
cell salvage 221–2
rHuEPO 25–32
RNA 37, 249
Rocky Mountain spotted fever 298
role plays, education 277
Roman Catholicism, transfusion bans 4
romiplostim 55, 61–2
see also peptide TPO-R agonists
routine tasks, blood management programs 280–1
Royal Society 67
running blood management programs 278–81
Russia, historical background 4
safety systems, blood management programs 281–2
St John’s wort, coagulopathy effects 154, 311
saline solutions 4, 67–8, 70–1, 109–10, 178–9, 186, 215–16, 222

rHuAT see recombinant human antithrombin
rHuEPO see recombinant human erythropoietin
rHuFVIIa see recombinant human FVIIa
rHuFVIII see recombinant human FVIII
rHuFXIII see recombinant human FXIII
rHuHb see recombinant human hemoglobin
rHuIL-11 see recombinant human interleukin-11
rHuSA see recombinant human serum albumin
ribavirin 62
riboflavin 36, 45, 47–8, 114
see also hematinics
rickettsia 297, 298
right to know principle of ethics 286–7
see also bills; charters; consumer . . . ; ethics; human . . . ; patients’ . . . ; principles
definition 285–6, 287–8
historical background 287
Ringer, Sydney 68, 70
Ringer’s crystalloid solution, concepts 70, 78, 221
risk–benefit ratios
see also individual topics
allogeneic transfusions 245, 246, 250–2, 291
BRAND decision-making mnemonic 247, 251–5, 258
cell salvage 221–2
rHuEPO 25–32
RNA 37, 249
Rocky Mountain spotted fever 298
role plays, education 277
Roman Catholicism, transfusion bans 4
romiplostim 55, 61–2
see also peptide TPO-R agonists
routine tasks, blood management programs 280–1
Royal Society 67
running blood management programs 278–81
Russia, historical background 4
safety systems, blood management programs 281–2
St John’s wort, coagulopathy effects 154, 311
saline solutions 4, 67–8, 70–1, 109–10, 178–9, 186, 215–16, 222
saline-enhanced thermal sealing 178–9

see also electrical currents for surgery

samples of equipment/drugs, education 277

sampling sites, phlebotomy 162

sargramostim 58–60

SARS see severe acute respiratory syndrome

Savitsky’s test 110

Sawyer et al. 21

scalpels 174–87

see also physical methods of hemostasis; surgery . . .

benefits 176

historical background 174–5, 176

Scheele, Karl W. 125

scoliosis syndromes 143

screening questions, surgery preparations 142

Seldinger method of inserting and arterial line 164

selective hepatic vascular occlusion, definition 182–3

selective occlusion of vessels 182–4

see also physical methods of hemostasis; tourniquets

self-education material, blood management programs 263, 275–6

Sengstaken–Blakemore tubes 186

sera, recombinant blood products 105, 293–4

serum calcium levels 10

serum sickness, antisera 236

severe acute respiratory syndrome (SARS) 236, 298

sevoflurane 194–5, 197

shock 184–7

SHOT risk control initiative, transfusions 253

sialylglycoprotein 23–32

see also recombinant human erythropoietin

sickle cell disease 29, 44, 48, 119, 120, 135, 146, 151, 224–5, 278, 312

cell salvage 224–5

clubs 278

definition 135, 224

HBOCs 120

hematinics 44, 48

hyperbaric oxygen therapy 135

PFCs 119

rHuEPO therapy 29, 44

surgery preparations 146, 151

treatments 29, 44, 135, 151

sideroblastic anemia 46

silver nitrate, hemostasis 94

simple facemasks, inhalational oxygen therapy 131–2

single donor apheresis platelet concentrates, definition 249

‘single-factor’ concentrates 232

skin and connective tissues, surgery preparations 143, 248–9

Smith vs Selby mature minor rule 290

smokers 148, 287, 290, 291

snake antivenom 241

Society for the Advancement of Blood Management 4, 6

sodium chloride crystalloid solution 70–1

sodium nitrate (NaNO2) 113, 114

solubility coefficient 126–7

soybeans 101

spacing factors, red blood cells 16

Speiss, B.D. 246

spike arrest changes, adaptation mechanisms to anemia 17–18

spinal injuries, EPO effects 25

spinal surgery 193, 195, 198

spleen 39, 181, 213

stakeholders, blood management programs 263, 275–6, 279–80

stand-by cell salvage 219

starch colloid solutions 68, 71–2, 78, 217

see also colloids; hydroxyethyl starch

Starling’s law 69

steering committees, blood management programs 269–71

stem cells 36–7, 51–64, 293–4

see also hematopoiesis

steps in blood management programs 262–82

storage guidelines, red blood cells 247–9

stories, education 324–6

STORMACT (Strategies to Reduce Military and Civilian Transfusion) 4

stresses 13, 160, 163–4, 273

iatrogenic blood loss 160, 163–4

oxygen consumption 13

stripping, Halstedian principles 175

stroke volume (SV), oxygen delivery equation 9–10, 13–14, 17, 76–7, 112–13, 116, 129, 302

strokes 119, 250–1, 252

structural issues, blood management programs 267, 269–70

Stuart-Prower factor 87

students, education 272–8, 323–6

sucralfate 164

superoxide dismutase (SOD) 111–12

supplemental oxygen, anemia treatments 17–18

surface modifications (conjugations), free hemoglobin 111–12

surgery 1–2, 5, 6, 47–8, 84, 139–59, 160–72, 173–87, 191–200

see also anesthesia; iatrogenic blood loss; physical methods of hemostasis

basics 175–6

bloodless medicine and surgery 1–2, 5, 183, 187

compression concepts 174, 184–6

drains 186, 192–3, 208

electrical currents 173, 177–9, 181

Halstedian principles 3, 175

heat uses 173, 174, 176–9

historical background 173–5

kinetic energy uses 181

light uses 175, 179–80

microwaves 175, 179

plasma gas uses 175, 180–1

positioning factors 187, 192–3, 313

preoperative blood management 3, 139–56, 166–8

selection issues 175

selective occlusion of vessels 182–4

techniques 175–6, 182

tools 176

vibration uses 181–2

surgery preparations 139–56, 166–8, 192–9, 313

ABL 139, 140, 149–56

age factors 141

algorithms 139–40, 145–6, 155, 168, 270–1, 275, 305–7, 311–13, 317–18

allergic reactions 144, 165, 247

anemia 141–56

body system reviews 143–4

BV 139, 140, 148–56, 204–8

cancers 143–4, 154

cardiovascular system review 143, 154

care plans 139–40, 149–50, 155, 313, 324
clotting problems 142–3, 145–7, 151–4
coagulation disorders 142, 144, 145–7, 151–4
documentation simplification tip 141
duration considerations 155
emergency trays 155, 156
ethnicity/race information 141
focused history taking 140–4, 311, 324
gender factors 141, 143, 148
HBmin 140, 148–56
historical background 139–44
laboratory tests 140, 144–5, 147, 160–3
mathematics 145–9
medications being taken 144, 154–5
musculoskeletal disorders 142–3
Napoleon Bonaparte analogy 154–5
patient education benefits 154, 162–3
physical examinations 144
positioning factors 187, 192–3, 313
preoperative work-up of accompanying disorders 145
preoperative work-up of anemia 144–5
preoperative work-up of impaired clotting 145–7
preparing the equipment 154–6
preparing the patient 140, 150–4
previous surgical procedures 142–3
preparing patients 144
preparing the equipment 154–6
preparing the patient 140, 150–4
previous surgical procedures 142–3
RBC loss estimates during surgery 148–9
screening questions 142
specific areas of inquiry 141–3
surgical field optimizations 154, 192–3, 214–15, 222–3, 313
sutures, selective occlusion of vessels 182
sympathetic nervous system, adaptation mechanisms to anemia 14–18
syndrome 143
syncope 143
synthesized EPO 25
Synthocytes 120
syphilis, transfusions 2, 203
systemic hemostatic drugs 81–9, 151–4, 311
see also antifibrinolytics; conjugated estrogens; desmopressin; hemostasis; vitamin K
T lymphocytes 52–3, 57, 235–7, 253, 298
see also CD4 . . . ; CD8 . . . ; cytotoxic . . . ; helper . . .
T (tense) form hemoglobin 12
Tabuse 175
tachycardia 144
Taylor, I. 285
teaching see education
temperature factors
anemia treatments 17–18
gas laws 126–7
oxygen consumption 13
terlipressin 94
testosterone effects, hematocrit levels 30–1
tetragalacturonic acid ester, hemostatic drugs 89
Th1/2 T helpers 253
thalassemia 48
theophylline, EPO hyporesponsiveness 26–7
thermal knife 173, 176–87
see also physical methods of hemostasis; surgery
thrombocytopenia 61–3, 94–5, 103, 115, 120, 144, 146, 152–4, 165, 221, 236, 238, 239–40, 255, 257
thrombocytosis, rHuEPO 24–5
thromboembolism 252
thrombopoietic growth factors 54–64
definition 54
first generation 54–5, 61
interleukins 55–6
second generation 55, 61–2
thrombopoietin (TPO) 53–64
thrombosis 25, 252, 280
thymidylates 36–7, 45
tissue adhesives/sealants (glues) 81, 90–5, 155–6, 217–18, 313, 317
see also fibrin sealants; hemostasis; local hemostatic agents
tissue extracts, hemostatic drugs 88–9
tissue handling, Halstedian principles 175
tissue healing 89–95, 128, 250–2
tissue perfusion, fluid management 76–8, 251–2
tissue repairs, oxygen consumption 13
tissues
oxygen give-up and tissue take-up processes 12–13, 16–18, 36–7, 110–11, 116–20, 247–9
oxygen usage considerations 12–13, 16–18
tobacco plants, recombinant blood products 101, 105
tomato plants, recombinant blood products 101
tonicity, definition 303
total vascular occlusion, definition 182–3
tourniquets 4, 81–2, 155, 174–5, 183–4, 313
see also selective occlusion of vessels complications 184
definition 183–4
historical background 174–5
military influences 184
timing factors 184
Toxoplasma gondii 298
TPO see thrombopoietin
TPO agonist antibodies 55
TPO/IL-3 fusion protein 54
tracheo-bronchitis 128
tracheostomy, iatrogenic blood loss 164–5
tranexamic acid 82, 83–4, 89, 94, 156, 168, 241
see also antifibrinolytics; hemostasis
immune system 251–8
imunosuppression problems 5, 219, 253
Jehovah’s Witnesses 1–3, 5, 6, 263, 265, 285, 291–5, 317
mortality rates 4, 252, 256, 287
outcome risk factors 250–2, 280
risks 245, 246, 250–8, 297–8
SHOT risk control initiative 253
side effects 245, 249, 251–8
sources of blood 245, 247
specialists 4–5
surgery preparations 148–56
thresholds 4–5, 16, 246, 250, 256–7
triggers 4–5, 16, 245, 246, 250–8
TRIM 251, 253
variable practices 7, 246–7, 279
transfusion-transmissible diseases 2, 3–4, 5, 201–3, 229–30, 246, 253–5, 297–8
see also hepatitis . . . ; HIV/AIDS; malaria; syphilis
see also allogeneic . . . ; principles
10/30 rule of Adams and Lundy 4–5, 246
bans 4
barbaric practices 245–6
benefits’ assessments 247, 250–2
blood management uses 245–58
blood viscosity levels 16, 69, 207
BRAND decision-making mnemonic 247, 250–8
concepts 5, 148–56, 245–58, 286–95
controversial aspects 5, 245
costs 5
critique 245–58, 287
definition 245
effects on the body 251–2
future prospects 5
hematinics 47
heterologous transfusions 245
historical background 1–8, 67–8, 81–2, 100–1, 109–10, 124–6, 160–1, 173–5, 201–2, 212–13, 229–30, 245–6
iatrogenic blood loss 168–9
rHuEPO 21–32, 39, 44, 47, 63, 141, 150–1
sickle cell disease 29, 44, 135, 151
stimulating agents other than rHuEPO 30–1
surgery preparations 150–4
thrombocytopenia 61, 63, 94–5, 103, 152–4, 236, 238, 239–40
ulcers 164, 169
vitamin K deficiencies 239
vitamins 43–9, 239
Trendelenburg position 192–3
trichloroacetic acid, hemostasis 94
triglycerides, heat in surgery 176
TRIM, transfusions 251, 253
trypsin 82
tumor cells, cell salvage 219, 221, 223–4, 225
tumor necrosis factor alpha 218
Tunnicliffe, Dr 109
tyrosines 22–3

Index 349

transfer forms, blood management programs 281, 316, 321–2
transferrin 38, 42, 230, 248–9, 300
see also plasma . . .
transfusion alternatives BRAND decision-making mnemonic 247, 256, 258
growth factors 62
historical background 1–5
Jehovah’s Witnesses 1–3, 5, 6, 263, 265, 291–5
transfusion alternatives BRAND decision-making mnemonic 247, 256, 258
growth factors 62
historical background 1–5
Jehovah’s Witnesses 1–3, 5, 6, 263, 265, 291–5
transfusion-free medicine and surgery 1, 5, 307–8
transfusion-transmissible diseases 2, 3–4, 5, 201–3, 229–30, 246, 253–5, 297–8
see also hepatitis . . . ; HIV/AIDS; malaria; syphilis
see also allogeneic . . . ; principles
10/30 rule of Adams and Lundy 4–5, 246
bans 4
barbaric practices 245–6
benefits’ assessments 247, 250–2
blood management uses 245–58
blood viscosity levels 16, 69, 207
BRAND decision-making mnemonic 247, 250–8
concepts 5, 148–56, 245–58, 286–95
controversial aspects 5, 245
costs 5
critique 245–58, 287
definition 245
effects on the body 251–2
future prospects 5
hematinics 47
heterologous transfusions 245
historical background 1–8, 67–8, 81–2, 100–1, 109–10, 124–6, 160–1, 173–5, 201–2, 212–13, 229–30, 245–6
iatrogenic blood loss 168–9
vaccines, recombinant blood products 105
valproate, coagulopathy effects 154, 165
Valsalva maneuver 193
vancomycin 92
varicella zoster (VZV) 236
vascular occlusion, selective occlusion of vessels 182–4
vascular tone, macrocirculatory adaptations to anemia 14–15
vasoconstrictors 82, 89–90, 94–5, 113, 127–36, 193–7
see also epinephrine . . . ; vasopressin
vasodilatory effects 14–18, 71, 112–13, 127–8, 194–6, 247–9
vasopressin 82, 85–6, 94, 156
see also desmopressin
vasopressor effects 113, 252
vena cava, total vascular occlusion 182–3, 193
ventilation patterns, anesthesia 196–7, 198
ventricular assist devices 166–8
see also extracorporeal circulation
Venturi mechanism 130–1
veracity principle of ethics 286–7
vibration uses in surgery 181–2
see also physical methods of hemostasis
videotapes, education 276–7
Vietnam War 4, 110, 213
vitamin A 36, 46, 47–8
vitamin B complex 18, 26–8, 36, 46, 48, 144
vitamin B6 26–8, 36, 46, 47, 144
see also hematinics
vitamin B12 26–8, 36, 44, 45, 47–8, 144
see also hematinics
vitamin C 18, 25–8, 36, 39–40, 45–6, 47–8, 114–15, 145–6, 154, 311
see also hematinics
anemia treatments 18, 39–40, 45–6
deficiencies 45–6, 143–4
definition 45–6, 48
HBOCs 114
iron 39–40, 48
rHuEPO 25–8
vitamin D 26
vitamin E 36, 46, 47–8, 311
see also hematinics
vitamin K 46–7, 48, 81, 82, 86–8, 89, 95, 101, 103, 143–4, 152–4, 231–41, 311
see also coagulation . . . ; factor . . . ; hemostasis
administration 87, 152–3
deficiencies 87, 95, 143–4, 147, 239, 311
definition 46–7, 81, 82, 86–7
historical background 82
side effects 87–8
treatments 239
types 86–7
vitamins 36, 43–9, 143–4, 311
see also folates; hematinics; individual vitamin; L-carnitine; riboflavin concepts 43–9
surgery preparations 143–4
volume balance basics 69
volume therapy 18, 67–79
see also fluid management
anemia treatments 18
see also volume-resuscitated anemia, concepts 14–18
von Willebrand disease (vWD) 82, 85–6, 88, 89, 120, 147, 151–4, 231–2, 238, 299–300, 307
von Willebrand factor (vWF) 82, 85–6, 89, 151–4, 231–2, 238, 241, 299–300, 307
definition 232
desmopressin 82, 85–6, 89, 151–4, 231–2, 238, 241
warfarin 87, 258
warming uses, anesthesia 196
washed blood, indirect cell salvage 212–17, 218, 219–21, 222–5
waste, cell salvage 215–17
The Watchtower (Jehovah’s Witnesses) 2, 293–4, 308
water, oxygen 126–7, 302
water jets 181
see also kinetic energy . . .
Watt, James 125
website resources, blood management programs 263, 265, 308, 318
weight and height factors, surgery preparations 141
West Nile virus 298
white cells 51–64, 163, 217, 235–7, 247–50, 253, 292–4
see also granulocyte . . . ; leukocytes; lymphocytes
WHO see World Health Organization
wines, asanguinous fluids 4, 67–8
World Health Organization (WHO) 3, 82, 145, 287, 307
World Trade Center terrorist attacks on September 11, 2001 4
World Wars 3–4
see also military influences
worm infestations, surgery preparations 143
Wren, Christopher 4, 67
y-carboxylation 81, 87–8, 101
see also vitamin K
zeolite cylinders, oxygen therapy 130–2
zidovudine 29
zinc 42–3, 47
Index compiled by Terry Halliday